BeyondSpring (NASDAQ:BYSI) Stock Price Up 1.3% – Should You Buy?

Posted by Tristan Rich on Jul 29th, 2026

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s share price traded up 1.3% during trading on Tuesday . The stock traded as high as $1.1850 and last traded at $1.1850. 6,587 shares changed hands during trading, a decline of 78% from the average daily volume of 29,945 shares. The stock had previously closed at $1.17.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

View Our Latest Stock Analysis on BeyondSpring

BeyondSpring Trading Up 1.3%

The business’s fifty day simple moving average is $1.55 and its 200 day simple moving average is $1.56. The stock has a market cap of $48.73 million, a P/E ratio of -8.46 and a beta of 0.43.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.49.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC boosted its position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 256,212 shares of the company’s stock after buying an additional 231,844 shares during the quarter. Geode Capital Management LLC owned approximately 0.64% of BeyondSpring worth $603,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 40.29% of the company’s stock.

About BeyondSpring

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.